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Abstract
Proadrenomedullin NH2-terminal 20 peptide (PAMP) and adrenomedullin (ADM) bind to teratocarcinoma cells. The effects of PAMP
and ADM on teratocarcinoma cells were investigated. 125I-PAMP bound to PA1 cells with moderate affinity (Kd 5 110 nM) to a single class
of sites (Bmax 5 110 000/cell). Specific 125I-PAMP binding was inhibited by PAMP (IC50 of 100 nM) but not ADM, calcitonin gene-related
peptide (CGRP), or amylin. Specific 125I-ADM binding was inhibited with high affinity by ADM, CGRP, and CGRP(8–37) (IC50 values
of 10, 10, and 15 nM respectively) but not PAMP or amylin. ADM elevated cAMP (ED50 value of 100 nM), whereas PAMP had no effect
on basal cAMP but inhibited the increase in cAMP caused by 10 nM ADM. Also, the increase in cAMP caused by ADM was inhibited
CGRP(8–37), suggesting that ADM is binding to CGRP receptors. ADM (100 nM) stimulated transiently c-fos mRNA, whereas PAMP
(1000 nM) had little effect; however, PAMP inhibited the increase in c-fos mRNA caused by ADM. ADM stimulated [3H]thymidine uptake
into PA1 cells, whereas PAMP inhibited the increase in thymidine uptake caused by ADM. These results indicate that ADM and PAMP
are both biologically active in teratocarcinoma cells. Published by Elsevier Science Inc.
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1. Introduction
Adrenomedullin (ADM) and its gene-related peptide
proadrenomedullin N-terminal 20 peptide (PAMP) are de-
rived from a 185-amino acid precursor molecule [12,14,39].
Originally isolated from pheochromocytoma, ADM has
been localized to the adrenal gland, lung, cardiac ventricle,
kidney, pancreas, and brain, especially the thalamus and
hypothalamus [7,30]. In the periphery, ADM is a potent
hypotensive agent interacting with receptors on endothelial
cells and vascular smooth muscle cells [5] and regulating
electrolyte homeostasis [32]. ADM inhibits ACTH secre-
tion from the pituitary, insulin secretion from the pancreas,
and catecholamine secretion from the adrenal gland [28].
PAMP is biologically active and it is a hypotensive agent
[4,15] that decreases catecholamine secretion [13,29,36].
ADM has sequence homologies with calcitonin gene-
related peptide (CGRP). The ADM receptor (G10D) binds
ADM but not CGRP with high affinity and stimulates ad-
enylyl cyclase [10]. The CGRP receptor binds the agonists
ADM and CGRP as well as the antagonist CGRP [8–37]
with high affinity [1,11,43]. Recently, it was found that
RAMP proteins are essential for the biologic activity of
CGRP and ADM receptors [20]. If the CRLR receptor was
combined with RAMP-1, a CGRP response resulted,
whereas if the CRLR receptor was transfected with RAMP-2,
an ADM response resulted [20]. Thus, RAMP proteins are
essential for proper CGRP and ADM receptor function.
Previously, we showed that ADM receptors are present
on ovarian, lung, glioma, and breast cancer cells [18,19,21],
and that many tumor cell lines express the peptide and
receptor for ADM. The actions of ADM can be suppressed
by monoclonal antibody (mAb)G6, which neutralizes
ADM. Because mAbG6 reduces the growth of breast, lung,
and ovarian cancer cells, ADM may function as an autocrine
growth factor in cancer cells [21]. Here the effects of PAMP
and ADM were investigated on teratocarcinoma cells.
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2. Methods
Human teratocarcinoma (PA1) and choriocarcinoma
(JAR) cells were obtained from ATCC and cultured in
RPMI-1640 media containing 10% heat-inactivated fetal
bovine serum (FBS). The cells were cultured in 5%CO2/
95% air at 37°C and were used in exponential growth phase.
PAI and JAR cells, which are adherent, were split (1/20)
weekly using trypsin-EDTA.
PA1 cells were fed twice weekly, and a day after feeding,
binding experiments were conducted. The cells were
washed three times with SIT medium (RPMI-1640 contain-
ing 3 3 1028 M Se2O3, insulin (5 mg/ml) and transferrin (10
mg/ml)). The cells were incubated in receptor-binding me-
dium (SIT medium containing 1% bovine serum albumin
and 1 mg/ml bacitracin) with 0.2 nM 125I-ADM or 125I-
PAMP (2200 Ci/mmol; Phoenix Pharmaceuticals, St. Jo-
seph, MO, USA) in the presence or absence of competitor.
After 1 h at 4°C, free peptide was removed by washing three
times in receptor binding medium. Peptide bound to the
cells was solubilized in 0.2 N NaOH and counted in a
gamma counter.
The ability of ADM or PAMP to alter cAMP was inves-
tigated. Confluent PA1 cells in 24-well plates were washed
three times in 0.5 ml of SIT medium and incubated with SIT
medium containing 1% bovine serum albumin, 1 mg/ml
bacitracin, and 200 mM isobutylmethylxanthine. After 20
min, peptides were added, and after a 5-min incubation at
37°C, 250 ml of supernatant was removed and 250 ml of
iced ethanol was added. The cell suspensions were mixed,
stored at 280°C until use, and assayed for cAMP by radio-
immunoassay [16].
The ability of ADM or PAMP to stimulate nuclear on-
cogene (c-fos) production was investigated. PA1 cells were
cultured with SIT medium containing 0.5% FBS. After 4 h,
the cells were treated with increasing doses of ADM. After
1 h, total RNA was isolated by using guanidine isothiocya-
nate. Ten micrograms of denatured RNA was separated in a
0.66M formaldehyde 1% agarose gel. The gel was treated
with ethidium bromide to assess RNA integrity. The RNA
was blotted onto a nytran membrane overnight, and the
membrane hybridized with cDNA probes (1.25 kb cDNA of
human c-fos labeled with 32P-dCTP with a Bethesda Re-
search Laboratories random priming kit [23]). The mem-
brane was exposed to Kodak XAR-2 film at 280°C for 1
day and the autoradiogram developed.
The ability of ADM to alter proliferation of PA1 cells
was investigated. When a monolayer of cells formed, SIT
medium containing 0.5% FBS was added followed by ADM
and/or PAMP. After 16 h, 3H-deoxyribose thymidine (106
cpm) was added for 2 h. The 24-well plates were washed
three time with cold PBS, one time with cold 5% trichlo-
roacetic acid, and one time with cold ethanol/ether (2:1).
After air drying, the plates were treated with 0.2 N NaOH
and counted in a b counter.
3. Results
Table 1 shows that 125I-ADM and 125I-PAMP bound
specifically to a wide variety of cells including pituitary
cancer, glioblastoma, choriocarcinoma, and teratocarci-
noma cells. Because 125I-PAMP bound best to PA1 terato-
carcinoma cells, its binding was further characterized.
125I-PAMP binding to PA1 cells was time dependent.
Total binding increased rapidly during the first 10 min and
then slowly for the next 50 min (Fig. 1). In contrast, non-
specific binding changed little as a function of time. The
difference between the two is specific binding, which in-
creased rapidly the first 10 min and slowly the next 50 min.
The ratio of specific/nonspecific binding was approximately
1:1.
125I-PAMP binding was investigated as a function of
ligand concentration. Fig. 2 shows that 125I-PAMP bound to
PA1 cells with moderate affinity (Kd 5 110 nM) to a high
density of sites (Bmax 5 110 000/cell). Table 2 shows the
specificity of binding. 125I-PAMP binding to PA1 cells was
inhibited by PAMP but not ADM, amylin, CGRP, or calci-
tonin. In contrast, 125I-ADM binding was inhibited by 1000
nM ADM or CGRP, but not amylin or PAMP.
125I-ADM binding was investigated as a function of
competitor concentration (Fig. 3). Specific 125I-ADM bind-
ing was inhibited by ADM in a dose-dependent manner by
unlabeled ADM and was half-maximally inhibited (IC50) by
10 nM ADM. In contrast, PAMP had no effect on 125I-ADM
binding even at 1000 nM. CGRP and CGRP [8–37] had
IC50 values of 10 and 15 nM.
The effect of ADM and PAMP on cAMP was investi-
gated. Fig. 4 shows that ADM elevated cAMP in a dose-
dependent manner with little stimulation at 1 nM and strong
stimulation at 1000 nM. The half-maximal effective dose
(ED50) was 100 nM for ADM, whereas PAMP had no effect
on basal cAMP. PAMP inhibited the ADM stimulation of
cAMP. Table 3 shows that PAMP, CGRP [8–37] and so-
matostatin (SST) had little effect on basal cAMP; however,
Table 1
Specific binding of ADM and PAMP
Cell line 125I-ADM 125I-PAMP
Pituitary cancer
GH3 137 6 52 106 6 33
AtT-20 0 0
Glioblastoma
U87 192 6 47 375 6 63
U138 577 6 78 147 6 34
U373 189 6 34 223 6 57
Teratocarcinoma
PA1 486 6 68 654 6 77
Choriocarcinoma
JAR 548 6 56 471 6 61
The mean cpm 6 SD of four determinations each repeated in quadru-
plicate is indicated using 0.5 3 106 cells.
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they significantly inhibited cAMP stimulated by 10 nM
ADM.
The effects of ADM and PAMP on nuclear oncogene
expression were investigated. Fig. 5 shows that 100 nM
ADM stimulated c-fos mRNA. The increase in c-fos caused
by 100 nM ADM was inhibited by 1000 nM PAMP,
whereas PAMP had little effect on basal c-fos.
The ability of ADM and PAMP to alter the proliferation
of PA1 cells was investigated. Table 4 shows that the
addition of 100 nM ADM increased the [3H]thymidine
uptake from 8825 to 14742 cpm. PAMP, in a dose-depen-
dent manner, reversed the increase in [3H]thymidine uptake
caused by ADM. As a positive control, 10% FBS increased
the [3H]thymidine uptake to 26263 cpm.
Fig. 1. 125I-PAMP binding. Total (F) and nonspecific (E) 125I-PAMP binding were determined. The mean value 6 SD of four determinations is indicated.
The difference between the two () represents specific binding. This experiment is representative of two others, and the lines are drawn point-to-point.
Fig. 2. Scatchard plot. Specific 125I-PAMP binding was determined as a function of 125I-PAMP concentration. The amount bound (B)/free (F) is plotted as
a function of the amount bound. The best-fit line is drawn assuming a single class of sites. This experiment is representative of three others.
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4. Discussion
Previously, we found that ADM bound with high affinity
to human cancer cell lines and human skin fibroblasts with
high affinity [17–19,21]. ADM increased cAMP, c-fos gene
expression, and proliferation of rat glioma C6 cells [23].
Here, the effects of ADM and PAMP on teratocarcinoma
cells were investigated.
Two types of ADM receptors have been characterized.
One type of ADM receptor that binds ADM but not CGRP
or CGRP [8–37] with high affinity is present in rat tissues
endothelial cells and rat vascular smooth muscle cells
[8,24–27]. A second type of ADM receptor was identified
in bovine aortic endothelial cells, neuroblastoma cells, and
L6 cells, which bind ADM, CGRP, and CGRP [8–37] with
high affinity [34,43]. There may be additional ADM recep-
tors such as the CGRP2 receptor, which binds Cys(ACM)
[2,7] CGRP with high affinity but not CGRP [8–37,38].
Previously, CGRP1 receptors were identified on F9 ter-
atocarcinoma cells [31]. CGRP caused chemotaxis and
stimulated the growth of F9 cells. Here, with PA1 cells,
CGRP and CGRP [8–37] inhibited binding of 125I-ADM
with high affinity (IC50 values of 10 and 15 nM, respective-
ly). In contrast, PAMP had little effect of 125I-ADM binding
(IC50 . 1000 nM). With PA1 cells, the increase in cAMP
caused by ADM was antagonized by CGRP [8–37]. These
results suggest that ADM binds to CGRP1 receptors stim-
ulating adenylyl cyclase in PA1 cells.
PAMP binds with moderate affinity to PA1 cells (Kd 5
110 nM). Previously, in vascular smooth muscle cells, 125I-
PAMP bound with moderate affinity (Kd 5 35 nM) to a
single class of sites (Bmax 5 4.5 3 106/cell) [9]. Specific
125I-PAMP binding to vascular smooth muscle cells mem-
branes was inhibited by GTPtS, suggesting that the PAMP
receptor interacts with a G protein [9]. Here, PAMP inhib-
ited the increase in cAMP caused by ADM. The PAMP
binding site in PA1 cells may interact with a guanine nu-
cleotide binding protein (Gi), inhibiting adenylyl cyclase.
Also, PAMP induces hypotension via a pertussis toxin-
sensitive mechanism, suggesting that Gi may be involved
[37]. The binding receptors for ADM and PAMP may be
distinct. ADM binds to a G protein-coupled receptor of
approximately 70 000 Da; 125I-PAMP is cross-linked to a
90 000-Da protein with disuccinimidyl suberate [9]. Also,
SST inhibited the increase in cAMP caused by ADM. Pre-
liminary data (T. Moody, unpublished) indicate that PA1
cells have mRNA for SST2 receptors. SST2 receptors bind
octreotide with high affinity and interact with Gi [3]. These
results suggest that ADM, PAMP, and SST bind to distinct
membrane proteins in PA1 cells.
ADM elevates cAMP and the increased cAMP may
stimulate protein kinase (PK) A. Subsequently, PKA will
phosphorylate protein substrates such as the cAMP response
element binding protein, CREB, which can enter the nu-
cleus and alter transcription of early oncogenes [40]. Here,
Table 2
Specificity of binding
Addition 125I-PAMP bound 125I-ADM bound
None 2590 6 236 728 6 78
PAMP, 1 mM 1110 6 109 735 6 18
ADM, 1 mM 2785 6 108 404 6 100
CGRP, 1 mM 2756 6 114 586 6 74
Amylin, 1 mM 2527 6 119 741 6 18
Calcitonin, 1 mM 2297 6 21 n.d.
The total cpm bound 6 SD of four determinations using PA1 cells (106)
is indicated; n.d., not determined. This experiment is representative of two
others.
Fig. 3. Specificity of binding. Specific 125I-ADM binding was determined as a function of ADM (F), CGRP (E), CGRP(8–37) (f) and PAMP ()
concentration. The mean value 6 SD of four determinations each repeated in quadruplicate is indicated.
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ADM increased the c-fos mRNA 4-fold after 1 h and the
increase in c-fos mRNA caused by ADM was reversed by
PAMP. Similarly, ADM increased c-myc and c-jun mRNAs
in PA1 cells (T. Moody, unpublished). The c-fos and c-jun
may form a heterodimer and increase transcription of
growth factor genes that have AP-1 sites [40]. PAMP in-
hibits the increase in cAMP caused by ADM. Previously,
PAMP inhibited voltage-gated Ca21 channels through a
pertussis toxin-sensitive G protein [37]. Also, PAMP-in-
duced hypotension was inhibited by a pertussis toxin-sen-
sitive drug [36].
ADM stimulated [3H]thymidine uptake in PA1 cells and
Swiss 3T3 cells [41]. Here, the increase in TCA-precipitable
DNA caused by ADM was reversed by PAMP by using
PA1 cells. These data suggest that PAMP may be a physi-
ological antagonist of ADM. Previously, it was found that
PAMP inhibited the proliferation of human neuroblastom
TGW cells [2]. It remains to be determined whether PAMP
will function as an antagonist of ADM in vivo.
In addition to stimulating proliferation, ADM may have
a role in development. In extraembryonic structures such as
giant trophoblastic cells, high levels of ADM and PAMP are
expressed [22]. High expression of ADM in trophoblastic
cells at the implantation site has been reported [42]. Because
ADM and PAMP are differentially expressed during devel-
opment, they may regulate differentiation in a paracrine
manner. Stem cells can differentiate into a wide variety of
Fig. 4. ADM elevates cAMP. The ability of ADM (solid bar) and PAMP (shaded bar) to increase cAMP was determined as a function of concentration. The
mean value 6 SD of four determinations is indicated. This experiment is representative of three others.
Fig. 5. ADM and c-fos mRNA. C-fos mRNA was determined in PAI cells
after (a, A) no additions, (b, B) 100 nM ADM, (c, C) 1000 nM PAMP, and
(d, D) 100 nM ADM 1 1000 nM PAMP. The c-fos mRNA (left) was
determined by Northern blot (A–D), whereas the RNA loading (right) was
determined by ethidium bromide staining (a–d). This experiment is repre-
sentative of two others.
Table 3
Cyclic AMP assay
Additions Fmol/50 000 cells after 5 min
None 0.5 6 0.2**
ADM, 10 nM 3.3 6 0.9
ADM 1 1000 nM PAMP 2.0 6 0.2*
PAMP, 1000 nM 0.5 6 0.1**
ADM 1 SST 1.8 6 0.5*
SST, 1000 nM 0.4 6 0.2**
ADM 1 CGRP(8–37) 1.2 6 0.4*
CGRP(8–37), 1000 nM 0.4 6 0.1**
The mean value 6 SD of four determinations is indicated P , 0.01; **P
, 0.05; *from 10 nM ADM using Newman–Keul’s multiple comparisons
test. This experiment is representative of three others.
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tissues, including teratocarcinoma [35]. The roles of ADM
and PAMP in development need to be explored further.
In summary, teratocarcinoma cells bind ADM and
PAMP specifically. ADM stimulates cAMP, c-fos mRNA,
and the proliferation of PA1 cells, whereas PAMP inhibits
the effects of ADM.
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